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Background: Pregnancy-related venous thromboembolism (VTE) is a major cause of maternal 
morbidity and mortality. A new risk assessment model for VTE in relation to pregnancy has 
been introduced in Sweden. We wished to determine the proportion of preventable VTE cases 
if the model had been in use and make a brief cost-beneﬁ  t analysis.
Methods: A hospital-based retrospective case-control study of all postpartum thromboembolic 
instances of deep venous thrombosis and pulmonary embolisms during a 16-year period. Large 
anamnestic risk factors at the time of delivery were assessed. We correlated the ﬁ  ndings with 
the new Swedish guidelines for thromboprophylaxis.
Results: We found 37 cases of postpartum VTE during the study period. Nineteen of all VTE 
cases (51%) and eight out of eleven of cases of pulmonary embolism (73%) had two or more large 
anamnestic risk factors, ie, they would have been subjected to thromboprophylaxis if the new 
guidelines had been used. The cost of each preventable VTE was lower than treating a VTE.
Conclusion: Approximately one-half of postpartum VTE cases and 70% of pulmonary emboli 
cases have at least two large risk factors and might be preventable using the new algorithm. 
From the perspective of the health care system the new recommendations appears to be 
cost-effective.
Keywords: thromboprophylaxis, low molecular weight heparin, scoring system, health care 
ﬁ  nancing, ultrasonography, phlebography
Introduction
Pregnancy-related venous thromboembolism (VTE) is a major cause of maternal mor-
bidity and mortality in Western countries (Drife 2003). Normal pregnancy is associated 
with a manifest shift of the coagulation and ﬁ  brinolytic systems towards hypercoagu-
lability. Although these changes are of physiological importance in minimizing the 
risk of blood loss during delivery, they also increase the risk of thromboembolism. 
Some major predisposing factors are increasing maternal age, operative delivery, 
immobilization, obesity, heart disease, malignancy, Caucasian descent, a history of 
thrombosis, thrombophilia, and familial thrombosis.
The incidence of VTE is reported to be about 13/10,000 pregnancies, about half 
occurring before delivery and the other half in the puerperal period (Lindqvist et al 
1999). Thus, during a six-week span, the risk of VTE increases roughly 5-fold as 
compared to the antepartum period. In addition, it has been shown that the puerperal 
risk of thromboembolism is highest in the immediate postpartum period (Salonen Ros 
et al 2001). Furthermore, preeclampsia and caesarean section only have an impact on 
thrombosis risk during the puerperal period (Lindqvist et al 1999). Therefore, a higher 
risk level is present over a shorter time span with the risk decreasing in time. Based 
on this knowledge, the Swedish medical establishment has implemented a risk score Vascular Health and Risk Management 2008:4(5) 1082
Lindqvist et al
model (presented below) for estimating the likelihood of 
pregnancy-related VTE. Factors having a 5-fold increased 
risk or multiples thereof are included. The model recom-
mends to whom, when, at what dose, and for how long throm-
bosis prophylaxis is recommended for pregnant women. 
Guidelines on the use of thromboprophylaxis have reduced 
deaths after cesarean delivery (Drife 2003).
The following study was conducted in the area of Malmö, 
Sweden, in an attempt to assess the number of risk factors 
among women who developed a VTE during the postpar-
tum period. We also present the national risk assessment 
model for VTE in relation to pregnancy and estimate the 
proportion of preventable cases, if the algorithm had been 
used during the study period. A brief cost-beneﬁ  t analysis 
is also included.
Methods
All women with VTE during the ﬁ  rst six weeks after delivery 
at Malmö University Hospital, MAS, between 1990 and 2005 
were identiﬁ  ed out of a total of 51,968 deliveries. There is 
one radiological clinic serving the entire Malmö area. By 
using national personal identiﬁ  cation numbers, all pregnant 
women during the study period were cross-matched against 
the diagnostic procedures they received, allowing the major 
proportion of VTE cases to be identiﬁ  ed. We also searched 
the diagnosis numbers for thromboembolic complications 
at the hospital during the ﬁ  rst six postpartum weeks. Only 
direct signs of  VTE were included, ie, contrast ﬁ  lling defects. 
Indirect signs of deep venous thrombosis (DVT) were not 
accepted. One woman had a diagnosis of DVT, but on 
our special interpretation, we found no direct signs of the 
thrombosis and she was excluded. As previously described 
in detail, we took all women who delivered (n = 2,384) in the 
prospective unselected pregnant cohort as a reference group 
(Lindqvist et al 1999). In brief, 2,480 unselected pregnant 
women were recruited in early pregnancy for detailed anam-
nesis and blood sampling. They were followed without inter-
vention, but special attention was paid to thromboembolic 
and bleeding complications. Not earlier than three months 
postpartum, the blood samples were analyzed. Previously, 
we have reported on the distribution of risk factors in this 
population (Lindqvist et al 2002b).
We defined VTE as a deep venous thrombosis or 
pulmonary embolism occurring during the ﬁ  rst six weeks 
postpartum. The phlebograms, computerized tomographies 
(CT), and ultrasonographies were interpreted by two radiolo-
gists. In Malmö, at the present time, our preference is to use 
CT before ventilation/perfusion scintography in diagnosing 
pulmonary embolism in order to lower the radiation dose 
to the fetus (0.05 mSi versus 2 mSi, as estimated by our 
radiophysics department).
Preeclampsia was defined as pregnancy-induced 
hypertension and proteinuria  0.3 g/1 (Albuminuria 
dipstick  1+). Pregnancy-induced hypertension was deﬁ  ned 
as a resting diastolic blood pressure  90 mm Hg measured on 
two occasions separated by an interval of at least ﬁ  ve hours, 
and developing after 20 weeks of gestation in a previously 
normotensive gravida.
We considered abruptio placenta as the diagnosis of 
such, commonly based on the presence of uterine pain and 
vaginal bleeding in combination with the ﬁ  nding of blood 
clots behind the placenta.
Overweight was deﬁ  ned as a maternal body mass index 
(BMI) measured at the ﬁ  rst visit to the antenatal health 
clinic of BMI (kg/m2)  28, which is one standard deviation 
(SD) above the mean of our pregnant population (Lindqvist 
et al 1999).
A heredity of thrombosis was deﬁ  ned as one or more 
thromboses in first-degree relatives (father, mother, or 
siblings) occurring before the age of 60. Immobilization was 
deﬁ  ned as strict bed rest for more than one week.
The price of  low molecular weight heparin (LMWH) used 
in our ﬁ  nancial analysis was the price paid by the hospital.
The Swedish risk assessment guidelines for VTE and 
thromboprophylaxis in relation to pregnancy is presented 
in Table 1. Risk factors included in the guideline and the 
weight they were given are shown in Tabel 1. Clinical 
recommendations as to whom, when, at what dose, and for 
how long thromboprophylaxis is recommended at different 
scores is presented in Table 2. The basis of the risk estimates 
have previously been published (Lindqvist et al 1999a, 
1999b; Lindqvist et al 2002b).
Statistics
The odds ratio (OR) for the risk of VTE was calculated 
by cross-tabulation with a 95% conﬁ  dence interval (CI). 
Relative risk was determined in terms of ORs (95% CI). 
All calculations were performed with SPSS software 
(Statistical Package for the Social Sciences, SPSS Inc., 
Chicago, IL, USA) and p values  0.05 were considered 
statistically signiﬁ  cant.
Results
The number of  VTEs over the 16 years we studied totaled 37, 
representing an incidence of puerperal VTE of  7.1/10,000. In 
Table 3 we present risk factors present among women with Vascular Health and Risk Management 2008:4(5) 1083
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postpartum VTE and our reference group. All VTEs were 
veriﬁ  ed by objective methods: ultrasound (n = 14), intrave-
nous phlebography (n = 25), CT (n = 8), and ventilation/perfu-
sion scintography (n = 2), or pulmonalis angiography (n = 2). 
Some women were examined by more than one method.
Table 4 shows the main outcome of this study, ie, the 
distribution of risk scores in the reference group as compared 
with the VTE group and to the subgroup of cases with 
pulmonary embolisms. Fifty-one percent (19/37) of the 
postnatal VTEs and 73% (8/11) of the cases with pulmonary 
embolisms had two or more anamnestic large risk factors. Of 
the three women with pulmonary embolisms and a low risk 
score (0 or 1), one had a protein S deﬁ  ciency, one a protein C 
deﬁ  ciency, and one an antithrombin deﬁ  ciency. The ﬁ  nal six 
years (2000–2005) showed a lower incidence of postpartum 
VTE (9/21,702 or 4.1/10,000) as compared to the ten previous 
years (1990–1999) (28/30,265 or 9.3/10,000), OR = 0.45, 
95% CI 0.2–0.95 as compared to the ﬁ  rst period.
Two women were stricken with puerperal VTE despite 
thromboprophylaxis. The ﬁ  rst had had two prior VTEs and 
protein S deﬁ  ciency. She was treated with normal dosage 
prophylaxis, although according to the algorithm she should 
have received high dosage; she suffered a VTE ﬁ  ve days after 
delivery. The second woman, who had had one prior VTE 
as well as a protein S deﬁ  ciency, had a rethrombosis ﬁ  ve 
days after delivery. She experienced painful bruising from 
the LMWH and was switched to warfarin after delivery. The 
LMWH was continued for three days according to standard 
practice at the time.
Table 5 presents a rough estimation of the cost of 
thromboprophylaxis as per the established routine in Sweden 
for women with a history of VTE (risk score 4). For these 
women prophylaxis is recommended from early second 
trimester until six weeks after delivery. Also estimated 
is the cost associated with the new algorithm. The data shows 
the cost-effectiveness of prophylactically treating women 
whose risk score is two or three. Finally, we have approxi-
mated the potential number of VTE cases that are prevent-
able employing both methods and have calculated the cost of 
preventing one VTE. If the cut-off level had been set at risk 
score 1, some 24% more of the VTEs would have been pre-
ventable. However, the direct cost per additional preventable 
case would have been considerable higher than treating the 
complication, ie, $13,051 (2,200 × 10/7 times 0.243).
Discussion
In this paper we report that about one-half of the puerperal 
VTEs and two-thirds of the subgroup with postpartum pulmo-
nary embolism were at an anamnestic risk score of at least two 
points, ie, these events might have been prevented if the new 
algorithm had been in use. In addition, the risk level of more 
Table 1 Riskscore – risk factors and their weight
1p (ie, 5-fold increased risk)
  Heterozygous  FV  Leiden
    Heterozygous protrombin gene mutation
  Overweight  ( 28 in BMI in early pregnancy)
  Cesarean  section
    Familial thrombosis less than 60 years
  Maternal  age   40 years
  Preeclampsia
  Abruptio  placenta
    Other large risk factor
2p (ie, 25-fold increased risk)
  Protein  S-deﬁ  ciency
  Protein  C-deﬁ  ciency
    Immobilization (ie, plaster-treatment, strict bed rest  1 week, or 
over-stimulation syndrome)1
  Lupus  antikoagulans2
  Cardiolipin  antibodies2
3p (ie, 125-fold increased risk)
  Homozygous  FV  Leiden
    Homozygous prothrombin gene mutation
 4p High risk (10% absolute risk of   VTE in relation to pregnancy)
    Prior venous thromboembolic event (VTE)
    Antiphospholipid syndrome (APS) without prior VTE2
Very high risk ( 15% absolute risk of  VTE)3
  Mechanical  heart  valves
  Continuous  warfarin  prophylaxis
  Antithrombin  deﬁ  ciency
  Repeated  thromboses
    APS with prior VTE2
1At immobilization during pregnant short term thromboprophylaxis is recommended, 
ie, during the risk period.
2Women with APS, lupus anticoagulants, or anticardiolipin antibodies are also 
recommended low-dose ASA 75mg /d.
3Women with “very high risk” are recommended high dose prophylaxis (ie, twice daily 
with anti factor X activity remaining before next injection).
Table 2 Management based on risk score (the sum of risk points 
in Table 1)
Risk score 0 No treatment
Risk score 1 No treatment
Risk score 2 Short term (7 days) LMH prophylaxis 
after delivery or during immobilization
Risk score 3 6 weeks of LWH prophylaxis after 
delivery*
Risk score  4 Antepartum prophylaxis, and at least 
6 weeks postpartum**
“Very high risk” High dose antepartum prophylaxis and at 
least 12 weeks of puerpal prophylaxis***
*Initiated 4 hours after delivery.
**Women with anamnesis of   VTE initiate the antepartum prophylaxis during second 
trimester.
***Prophylaxis is initiated as early as possible and sometimes before pregnancy.Vascular Health and Risk Management 2008:4(5) 1084
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than 70% of the subgroup with pulmonary emboli would 
have warranted LMWH prophylaxis according to the new 
algorithm. Recalling that approximately two-thirds of lethal 
VTEs occur in the postnatal period, approximately one-half 
of the severe postnatal cases might have been preventable.
It should be noted that the model makes provision for 
“other large risk factors”. This will permit clinicians to insert 
factors not included in the model, enabling them to add an 
extra point or points to the risk score based on their judg-
ment in such cases as, women with a severe family history 
of thromboembolism, women with cancer, women who have 
been treated for cancer, or extremely obese women.
To the best of our knowledge there are no reports of the 
risk reduction afforded by thromboprophylaxis in obstetric 
patients. Approximately 71% to 75% risk reduction is 
reported after general surgery (Mismetti et al 2001). Since 
pregnant women are generally younger, healthier, and have 
less co-morbidity than the general population of  VTE among 
women, the relative risk reduction is presumably higher.
The model does not account for the 30% increased risk 
among smokers or for differences occasioned by parity 
(Lindqvist et al 1999). Before the present risk score model 
was accepted for national implementation, an internet-based 
alternative was also proposed, which took these differences 
into consideration and gave an estimation of the absolute risk 
of VTE (Lindqvist et al 2002a).
Friedrich and colleagues (1996) found women with 
protein S deﬁ  ciencies to be especially prone to postpar-
tum VTE. Both women who experienced VTE despite 
thromboprophylaxis, exhibited a protein S deﬁ  ciency and 
Table 3 Risk factors for VTE in study and reference groups
Postpartum VTE group Control group Odds ratio
(n = 37) % (n = 2384) % 95% CI
Maternal characteristics
Maternal age (years)
   40 36 97.3% 2340
   40 1 2.7% 26 1.1% 2.5 (0.3–18.9)
Preeclampsia
 No 31 83.8% 2345
 Yes 6 16.2% 39 1.6% 11.6 (4.6–29.5)
Cesarean section
 No 22 59.5% 2314
 Yes 15 40.5% 233 9.8% 6.8 (3.4–13.2)
Familial thrombosis (ﬁ  rst degree relatives  60 years)
 No 31 83.8% 2257
 Yes 5 13.5% 127 5.3% 2.9 (1.1–7.5)
 missing 1
Anamnesis of venous thromboembolism
 No 35 94.6% 2376
 Yes 2 5.4% 8 0.3% 17.0 (3.5–83)
Body mass index (Kg/m2)
   28 26 70.3% 2067
   28 9 24.3% 317 13.3% 2.3 (1.05–4.8)
 Missing 2
Immobilization
 No 26 70.3% na
 Yes 10 27.0% na na
 Missing 1
Abruptio placenta
 No 33 89.2% 2371
 Yes 3 8.1% 13 0.5% 16.6 (4.5–61)
 Missing 1Vascular Health and Risk Management 2008:4(5) 1085
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rate of cesarean sections with age (Lindqvist et al 1999). It was 
considered essential to include high age as a large risk factor. 
Around 10% of our pregnant population is above 35 years of 
age, but only some 1.1% of all women are above 40. The risk 
of VTE grows with increasing age. For this reason age  40 
was included in our model. Some changes were made to 
conform clinical practice. Homozygous factor V Leiden (FVL) 
represents 16- to 80-fold increased risk of VTE (Martinelli 
et al 2001; Juul et al 2004), but this factor was allotted 3 points 
(ie, a 125-fold increase). Women with homozygous FVL 
always receive six weeks of postpartum prophylaxis and, if 
they have additional large risk factors, antenatal prophylaxis 
early postnatal VTE (one at risk score 4 and one at very 
high risk). There may be indication for high dosage prophy-
laxis in the immediate postnatal period among women with 
protein C or protein S deﬁ  ciencies, due to the initial depres-
sion of protein S and protein C levels. Therefore, the current 
routine for women with protein S or protein C deﬁ  ciency if 
one switches to warfarin postpartum is to accompany the 
warfarin treatment with LMWH for one week.
Not all variables in the risk table have been shown to 
have a roughly 5-fold increased risk.
Maternal age  35 is an established risk factor (Drife 2004), 
although the heightened risk has been related to an increased 
Table 4 Distribution of risk score in reference and study groups
Reference group Postpartum VTE group Postpartum pulmonary 
emboli
(n = 2384) (%) (n = 37) (%) (n = 11) (%)
Risk score*
  Risk  score  0 1758 74% 10 27.0% 2 18.2%
  Risk  score  1 515 22% 9 24.3% 1 9.1%
  Risk  score  2 96 4.0% 10 27.0% 4 36.4%
  Risk  score  3 7 0.3% 3 8.1% 2 18.2%
  Risk  score   4 8 0.3% 5 13.5% 1 9.1%
*Risk score based on anamnestic variables present at delivery.
Table 5 Estimated cost for thromboprophylaxis of both established and according to new algorithm
Established routine New routine 
Prophylaxis to women with 
prior VTE
High risk according to algorithm 
Risk score 3 Risk score 2
Time of prophylaxios/women 30 weeks1 6 Weeks 1 Week
Cost per week $10 $10 $10
Incidence in pregnant population2 0.3% 0.3% 4%
Number of women per 10,0002 30 30 400
Estimation of cost in population per 
10,0003
30*$10*30
$9000
30*$10*6
$1800
400*$10*1
$4000
  Cost per 10,000 women =$9000 $5800
Expected no of  VTE 10% 7/10,0004
Possible preventable VTE cases per 
10,000 pregnancies6
3 3.45
Cost per preventable VTE case $3000 $1700
Cost per patient (CPP) price for VTE7
  Deep venous thrombosis $5580
 Pulmonary  emboli $7836
1Some 24 weeks during pregnancy and 6 weeks after delivery.
2According to our prior data (Lindqvist et al 2002b).
3Only including cost of LMWH, about $10/week.
4Data from this and prior study (Lindqvist et al 1999).
5Data from this study about 50% preventable.
6Possible preventable cases assuming 100% riskreduction.
7According to Swedish National Board of Health (Socialstyrelsen) 2006.Vascular Health and Risk Management 2008:4(5) 1086
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is also given. Due to the infrequent occurrence of these rare 
variables, their adjustment will not have a great effect on the 
discriminative potential of the model.
Approximately half of all VTE occur among women 
with risk score 0 or 1 and are not preventable by the present 
risk model. By changing the risk level of prophylaxis to 
risk score 1, some 25% to 40% more pregnant women 
(depending on the number of cesarean deliveries) would 
be treated, resulting in another 25% of the VTEs being 
possible to prevent. However, at this lower risk level a care-
ful analysis of increased bleeding complications is needed, 
especially if the prophylaxis is initiated antepartum. Women 
with antepartum thrombosis prophylaxis have a 4-fold 
increased risk of profuse hemorrhage during delivery and a 
6-fold increased risk of postpartum anemia (Lindqvist and 
Dahlbäck 2000). Therefore, it is our practice to initiate all 
thromboprophylaxis four hours after delivery in order to keep 
bleeding complications low.
The current paper includes only risk factors that could 
be ascertained by anamnesis. Since the introduction of this 
risk model (Lindqvist et al 2006), abruptio placentae has 
been added as a signiﬁ  cant risk factor (Preston et al 1996; 
Prochazka et al 2003, 2007).
For 50 years, the Royal College of Obstericians and 
Gynecologists (RCOG) have collected data on lethal throm-
boembolism as a result of their conﬁ  dential enquiries into 
maternal deaths (Drife 2004). Prevention of VTE has been 
a major issue in their attempt to lower maternal mortality. 
Their model, although similar to ours, differs in several 
ways, the main difference being that the RCOG includes 
all risk factors, while we consider only large ones. Increas-
ing age is a risk factor, but not a discriminative one. In the 
English model, preeclampsia is regarded as a risk factor both 
ante- and postpartum, whereas we only take it into account 
postpartum (Lindqvist et al 1999). We have concluded that 
the increased risk for multiparity is too small to be included 
in our model, but it is included by the RCOG (Lindqvist et al 
1999). In addition, the British model includes several risk 
factors for which we believe insufﬁ  cient data on the size of 
risk is available at present. However, several of these factors 
are candidates for future inclusion in our model. The British 
model also recommends short-term postnatal prophylaxis 
for three to ﬁ  ve days. If this should prove effective, it will 
facilitate the clinical management of women at increased 
risk. In Sweden, we still believe that at least seven days of 
prophylaxis is needed postpartum.
Although it was not a predetermined analysis, the ﬁ  nding 
of a lower thrombosis incidence during the second time period 
(2000–2005) might be attributed to the use of the algorithm 
in lowering the postpartum incidence of thrombosis. A local 
awareness of an increased risk among women with multiple 
large risk factors caused clinicians at our hospital to begin 
using the model before it was ofﬁ  cially introduced in 2005.
Economic factors
There was an almost a 4-fold lower direct cost of  LMWH as 
compared to the cost of treating VTEs. In addition, postnatal 
thromboprophylaxis has the potential of cutting in half the 
incidence of pregnancy-related pulmonary embolism, thereby 
lowering maternal mortality by one-twelfth (assuming that 
about one-sixth of maternal deaths are due to pulmonary 
embolism) (Drife 2003). Furthermore, we have not taken 
into consideration long-term morbidity, negative impact 
on quality of life among VTE patients (Kahn et al 2002), 
or to other indirect costs. The new recommendations for 
postpartum prophylaxis involve no additional expense 
other than LMWH, ie, no additional visits or laboratory 
tests. However, women with a history of VTE (risk score 
4) are usually scheduled for two visits to the physician, one 
at the beginning of the second trimester and one in the 34th 
week. In addition, prothrombin time, APTT, and platelet 
count is performed in second trimester and during delivery, 
and platelets are also measured two weeks after initiation 
of thromboprophylaxis. Thus, prophylactic postpartum 
treatment according to the new algorithm appears to be 
very favourable for the health care system, especially 
when compared to the cost of treating cases of deep venous 
thrombosis and pulmonary embolism.
Our ﬁ  ndings indicate that about half of puerperal VTE 
cases and two-thirds of pulmonary emboli cases have at least 
two large risk factors (ie, risk score 2). Thus, employing the 
risk score model presented here, approximately half of all 
severe VTE cases might be preventable.
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